Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other 1

Conditions

Breast Neoplasms 2321Neoplasms 1688Prostatic Neoplasms 1187Lung Neoplasms 914Colorectal Neoplasms 875Carcinoma, Non-Small-Cell Lung 849Leukemia, Myeloid, Acute 585Pancreatic Neoplasms 573Multiple Myeloma 545Carcinoma, Hepatocellular 515Brain Neoplasms 513Neoplasm Metastasis 462Head and Neck Neoplasms 459Melanoma 414Ovarian Neoplasms 409Glioblastoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 388Stomach Neoplasms 371Uterine Cervical Neoplasms 359Squamous Cell Carcinoma of Head and Neck 356Rectal Neoplasms 335Recurrence 334Hematologic Neoplasms 327Sarcoma 324Lymphoma 314Colonic Neoplasms 314Triple Negative Breast Neoplasms 285Urinary Bladder Neoplasms 283Glioma 278Carcinoma, Renal Cell 278

Interventions

Letrozole 2LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Cyproterone acetate, ethinyl estradiol drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Progesterone Resistance × 1 year × Clear all
NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Fudan University

Phase 2/3 Recruiting
29 enrolled
GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡